Xeris Biopharma Holdings Inc (XERS)’s latest performance is not what we had anticipated

On Friday, Xeris Biopharma Holdings Inc (NASDAQ: XERS) opened higher 2.87% from the last session, before settling in for the closing price of $4.60. Price fluctuations for XERS have ranged from $1.11 to $3.07 over the past 52 weeks.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

A company in the Healthcare sector has jumped its sales by 232.02% annually for the last half of the decade. Company’s average yearly earnings per share was noted 44.46% at the time writing. With a float of $123.33 million, this company’s outstanding shares have now reached $136.27 million.

Xeris Biopharma Holdings Inc (XERS) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Xeris Biopharma Holdings Inc is 10.71%, while institutional ownership is 38.80%. The most recent insider transaction that took place on Nov 27, was worth 10,098. In this transaction Director of this company bought 5,400 shares at a rate of $1.87, taking the stock ownership to the 5,400 shares. Before that another transaction happened on Nov 20, when Company’s insider bought 28,000 for $1.95, making the entire transaction worth $54,600. This insider now owns 1,176,912 shares in total.

Xeris Biopharma Holdings Inc (XERS) Performance Highlights and Predictions

If we go through the results of last quarter, which was made public on 9/29/2023, the company posted -$0.09 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.12) by $0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 44.46% per share during the next fiscal year.

Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators

Check out the current performance indicators for Xeris Biopharma Holdings Inc (XERS). In the past quarter, the stock posted a quick ratio of 1.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.60.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.23 in one year’s time.

Technical Analysis of Xeris Biopharma Holdings Inc (XERS)

Let’s dig in a bit further. During the last 5-days, its volume was 1.56 million. That was inferior than the volume of 2.4 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 91.63%. Additionally, its Average True Range was 0.15.

During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 90.38%, which indicates a significant decrease from 100.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.81% in the past 14 days, which was lower than the 79.17% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $2.32, while its 200-day Moving Average is $2.28. However, in the short run, Xeris Biopharma Holdings Inc’s stock first resistance to watch stands at $2.92. Second resistance stands at $2.97. The third major resistance level sits at $3.07. If the price goes on to break the first support level at $2.77, it is likely to go to the next support level at $2.67. Assuming the price breaks the second support level, the third support level stands at $2.62.

Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats

There are currently 138,125K shares outstanding in the company with a market cap of 396.40 million. Presently, the company’s annual sales total 110,250 K according to its annual income of -94,660 K. Last quarter, the company’s sales amounted to 48,320 K and its income totaled -12,190 K.